Aileron Therapeutics IncNASDAQ:ALRN
- LAST PRICE2.5800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.6100/ 2
- Ask / Lots2.6500/ 20
- Open / Previous Close--- / 2.5800
- Day Range---
- 52 Week Range
- Volume27
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALRN |
|---|---|---|
| 09:32 ET | 1069 | 2.73 |
| 09:42 ET | 3000 | 2.8198 |
| 09:46 ET | 3612 | 2.7442 |
| 09:48 ET | 700 | 2.65 |
| 09:53 ET | 750 | 2.645 |
| 09:55 ET | 2500 | 2.572 |
| 10:00 ET | 4321 | 2.55 |
| 10:02 ET | 3244 | 2.6517 |
| 10:04 ET | 1946 | 2.71 |
| 10:27 ET | 665 | 2.675 |
| 10:33 ET | 585 | 2.74 |
| 10:42 ET | 350 | 2.6 |
| 10:49 ET | 100 | 2.75 |
| 12:10 ET | 100 | 2.74 |
| 12:21 ET | 100 | 2.78 |
| 12:48 ET | 226 | 2.6709 |
| 12:53 ET | 6571 | 2.6599 |
| 12:55 ET | 1000 | 2.72 |
| 01:02 ET | 400 | 2.73 |
| 01:04 ET | 1000 | 2.73 |
| 01:11 ET | 900 | 2.71 |
| 01:24 ET | 2500 | 2.7117 |
| 01:27 ET | 770 | 2.765 |
| 01:33 ET | 100 | 2.81 |
| 01:42 ET | 4537 | 2.8501 |
| 01:44 ET | 2935 | 2.74 |
| 01:45 ET | 1199 | 2.7525 |
| 01:56 ET | 200 | 2.71 |
| 02:05 ET | 367 | 2.66 |
| 02:14 ET | 125 | 2.59 |
| 02:23 ET | 100 | 2.59 |
| 02:30 ET | 3405 | 2.745 |
| 02:32 ET | 6595 | 2.7304 |
| 02:54 ET | 9517 | 2.66 |
| 02:57 ET | 9875 | 2.68 |
| 03:08 ET | 11428 | 2.525 |
| 03:10 ET | 1749 | 2.51 |
| 03:17 ET | 1993 | 2.51 |
| 03:19 ET | 2253 | 2.58 |
| 03:28 ET | 1209 | 2.53 |
| 03:33 ET | 100 | 2.5 |
| 03:35 ET | 3934 | 2.6 |
| 03:37 ET | 200 | 2.57 |
| 03:39 ET | 150 | 2.599 |
| 04:00 ET | 735 | 2.58 |
Nov 14, 2024
*DJ Aileron Therapeutics 3Q Loss/Shr 27c >ALRN, from 4:15PM ET on Thursday Nov 14, 2024 by Dow Jones
4:15PM ET on Thursday Nov 14, 2024 by Dow JonesAileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights, from 4:15PM ET on Thursday Nov 14, 2024 by Dow Jones
4:15PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Oct 31, 2024
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma, from 7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
7:30AM ET on Thursday Oct 31, 2024 by Dow Jones*DJ Aileron Therapeutics And Advancium Health Network Announce An Exclusive Option Agreement For The Acquisition Of ALRN-6924 For Retinoblastoma >ALRN, from 7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aileron Therapeutics Inc | 55.9M | -0.8x | --- |
BioVie Inc | 55.2M | -0.5x | --- |
Elicio Therapeutics Inc | 55.2M | -1.0x | --- |
Connect Biopharma Holdings Ltd | 54.7M | -2.6x | --- |
Vor Biopharma Inc | 54.7M | -0.5x | --- |
Boundless Bio Inc | 57.3M | -0.9x | --- |
Company Information
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Contact Information
- Headquarters
- 12407 N. Mopac Expy., Suite 250 #390AUSTIN, TX, United States 78758
- Phone
- 617-995-0900
- Fax
- 617-995-2410
Executives
- Independent Chairman of the Board
- Josef Von Rickenbach
- President, Chief Executive Officer, Director
- Brian Windsor
- Interim Chief Financial Officer
- Timothy Cunningham
- Director
- Manuel Alves Aivado
- Independent Director
- Reinhard Ambros
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $55.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.25 |
EPS | $-3.11 |
Book Value | $20.12 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
